India's COVID-19 caseload rises to 90.95 lakh with 45,209 new cases; toll reaches 1,33,227

-

New Delhi: India's COVID-19 tally rose to 90.95 lakh on Sunday with 45,209 new cases, while the recoveries surged to 85,21,617, according to the Union Health Ministry's data.

The death toll reached 1,33,227 with 501 more fatalities, while total coronavirus cases mounted to 90,95,806, the data updated at 8 am showed.

The number of active cases remained below five lakh for the 12th consecutive day.

The total recoveries have surged to 85,21,617, pushing the national recovery rate to 93.69 percent, while the COVID-19 case fatality rate has declined to 1.46 percent.

There are 4,40,962 active cases in the country as on date which comprise 4.85 percent of the total caseload, the data stated.

India's COVID-19 tally had crossed the 20-lakh mark on 7 August, 30 lakh on 23 August and 40 lakh on 5 September.

It went past 50 lakh on 16 September, 60 lakh on 28 September, 70 lakh on 11 October, crossed 80 lakh on 29 October, and surpassed 90 lakh on 20 November.

According to the ICMR, over 13.17 crore samples have been tested up to 22 November with 10,75,326 samples being tested on Saturday.

The 501 new fatalities include 111 from Delhi, 62 from Maharashtra, 53 from West Bengal, 25 each from Kerala and Haryana, 24 from Uttar Pradesh, 23 from Punjab, 22 from Chhattisgarh and 20 from Karnataka.

Total 1,33,227 deaths reported so far in the country include 46,573 from Maharashtra followed by 11,641 from Karnataka, 11,586 from Tamil Nadu, 8,270 from Delhi, 7,976 from West Bengal, 7,524 from Uttar Pradesh, 6,927 from Andhra Pradesh, 4,595 from Punjab and 3,846 from Gujarat.

The health ministry stressed that more than 70 per cent of the deaths occurred due to comorbidities.

"Our figures are being reconciled with the Indian Council of Medical Research," the ministry said on its website, adding that state-wise distribution of figures is subject to further verification and reconciliation.



from Firstpost India Latest News https://ift.tt/395zlgw
Press Trust of India

Comments

Post a Comment

Popular posts from this blog

Both COVID-19 vaccine doses needed for good protection against B16172 variant

-
It’s been a concerning few weeks in the UK, with the B16172 variant first taking hold and then spreading to become dominant. This more infectious form of the virus, initially identified in India, is what we’re now going to have to live with – unless it is out-competed by another variant in the future. Worryingly, experts had predicted that B16172 might be able to escape some of the effects of vaccines, which if true would threaten to derail the UK’s plans to finish lifting restrictions from the end of June. However, Public Health England (PHE) has looked at the ability of various variants to evade immunity and says that the UK’s vaccines remain effective against the variants circulating, including B16172. On the surface, this looks like good news. But delve a bit deeper, and things get more complicated, says Paul Hunter, professor of medicine at the University of East Anglia. PHE’s research found a little drop-off in protection against B16172 among people who were fully vaccinated.
Read more

New coronavirus variant emerge in India: How should our COVID response change?

-
Image
After genome sequencing of over 10,000 COVID-19 cases in India, researchers have discovered a new variant with two new mutations which may be better at evading the immune system. In 15-20 percent of samples from the Indian state of Maharashtra (the state accounting for 62 percent of cases in the country) a new, double mutation in key areas of the virus has been detected. These are now known as the E484Q and L452R mutations. What makes the variant different? Both these mutations are concerning because they are located in a key portion of the virus – the spike protein – that it uses to penetrate human cells. Spike proteins attach via a “receptor binding domain”, meaning the virus can attach to receptors in our cells. These new mutations include changes to the spike protein that make it a “better fit” for human cells. This means the virus can gain entry more easily and multiply faster. Given what we have seen with other similar mutations , it might also make it harder for our immu
Read more

Aditya L1 Mission: Spacecraft is nearing its final phase, says ISRO chief

-
Aditya L1 spacecraft is nearing its final phase, and manoeuvres to enter the L1 point are expected to be completed by January 7, 2024, according to ISRO Chairman S Somanath. “Aditya is on the way. I think it has reached almost its final phase,” the ISRO chief told PTI on the sidelines of an event organised at VSSC to commemorate the 60th year of the First Sounding Rocket Launch. Aditya L1, India’s first space-based mission to study the Sun, was successfully launched on September 2 from the Satish Dhawan Space Centre (SDSC) in Sriharikota. The spacecraft, after travelling about 1.5 million km from Earth over 125 days, is expected to be placed in a Halo orbit around the Lagrangian point L1, considered closest to the Sun. He said that the last preparations for the spacecraft’s entry into the L1 point are currently underway incrementally.”Possibly by January 7th, the final manoeuvres will be done for entering into the L1 point,” Somanath added. Among other tasks, it will capture and tr
Read more